About Us
Our Story
Team
Careers
News
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Select specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Confirm Password
A
Myeloma 2022: Challenges and Path Forward
By
UChicago Medicine
FEATURING
Andrzej Jakubowiak
August 19, 2022
1 Comment
Login to view comments.
Click here to Login
Related Content
AUTOPLAY
ON
12:38
SOHO 2022 Tenth Annual Meeting
SOHO 2022 DEBATE: Bispecific Antibodies vs. CAR-T for R/R MM - Defen…
Feat.
S. Usmani
04:08
CancerGRACE
CAR T-Cell Therapy Side Effects for Blood Cancers
Feat.
A. Goodman
05:56
ASH 2022 Conference Coverage
ASH 2022 Myeloma XI Trial: Defining the Optimal Duration of Lenalido…
Feat.
G. Morgan
31:51
Indy Hematology Review
Treating Multiple Myeloma: The Cure Is Within Reach - Goals of Curre…
Feat.
K. Anderson
04:31
ASH 2022 Conference Coverage
ASH 2022 GRIFFIN Trial Final Analysis: D-RVd in Clinically Relevant …
Feat.
A. Chari
15:54
Paul Richardson
Emerging Strategies in the Management of Relapsed MM
30:59
Houston Methodist Hospital
Overview of Advances in Multiple Myeloma
Feat.
S. Ganguly
09:09
Douglas W. Sborov
IMS 2022 Final Analysis of the GRIFFIN Trial: Daratumumab + Lenalido…
34:48
Kenneth Anderson
MM Cured in 2030 - What Are the Next Steps?
Feat.
K. Anderson
21:38
Rahul Banerjee
CAR-T Therapy in Myeloma: What's Here and What's Coming So…
06:58
Saurabh Chhabra
Summary of the MAMMOTH Trial in R/R Myeloma
10:08
ASH 2022 Conference Coverage
ASH 2022 Maintenance Therapy Cessation for Sustained MRD Negative MM…
Feat.
N. Korde
06:41
Hamza Hashmi
Idecabtagene Vicleucel vs. Ciltacabtagene Autoleucel: A Sophie'…
10:09
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Next Questions for MM in the Coming 5-10 Years
Feat.
T. Martin
24:19
Dana-Farber Cancer Institute
Phase 3 DETERMINATION Trial: RVd ± ASCT & Lenalidomide Maintenan…
Feat.
P. Richardson
45:43
MedNews Week
Multiple Myeloma in 2022: Developments, Directions, and Disparities
Feat.
J. Mikhael
13:46
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Bispecific T-Cell Engagers - Early Data and Where Will We…
Feat.
R. Orlowski
24:01
ASH 2022 Conference Coverage
ASH 2022: First Relapse in Multiple Myeloma - How to Pick the Next B…
Feat.
Y. Efebera
34:28
2022 Community Oncology Conference
Treatment Conundrums in Myeloma
Feat.
S. Giralt
33:28
Cleveland Clinic Taussig Cancer Institute
Management of Relapsed/Refractory Multiple Myeloma
Feat.
F. Anwer
